Profitable pills: where to find the best biotech stocks

Marek Poszepczynski of the International Biotechnology Trust highlights three top biotech stocks to buy now.

A professional investor tells us where he'd put his money. This week: Marek Poszepczynski of the International Biotechnology Trust highlights three top biotech stocks.

Biotechnology is rightly classified as a growth sector, but not all companies have the same earnings potential. The drugs addressing the highest unmet medical needs tend to produce significant profits and consistent cash flows. Products that either cure a previously untreatable disease or improve patients' quality of life will sell well and are more likely to benefit from reimbursements by governments and health insurers.

Ideally, the product should be able to maintain a dominant position in its therapeutic area for a long period of time. A company is better able to protect its drug pricing and profitability if it faces fewer competitors. We have selected three stocks to fit these criteria, each with a different risk profile to cater for a variety of risk appetites.

Help for HIV and hepatitis patients

Gilead (Nasdaq: GILD)

But while the overall outlook for Gilead is robust, investors should be aware that the growth potential for this company is slowing as it is hard for such a large firm to expand rapidly. Investors with a higher risk appetite could look to smaller, faster-growing firms such as Vertex or Insmed.

The gold-standard cystic fibrosis drug

Vertex (Nasdaq: VRTX)

As this disease only affects a relatively small number of patients, the company has received orphan-drug status (this is granted to treatments for rare diseases). This allows Vertex to charge a high price for its product and the portfolio is also shielded from competition by Vertex's intellectual-property rights.

A crucial antibiotic

Insmed

(Nasdaq: INSM)

Investing in the antibiotic space has been tough in recent years despite the clear and growing unmet need. However, Insmed has succeeded in developing and launching Arikayce. Initial sales look robust.

Recommended

A low-risk way to beat inflation
Share tips

A low-risk way to beat inflation

Demand for care-home places is strong and the sector should be able to raise prices ahead of costs, says Max King.
8 Aug 2022
Three stocks to provide income and growth in good times and bad
Share tips

Three stocks to provide income and growth in good times and bad

Professional investor Matthew Page of the Guinness Global Innovators fund picks three resilient stocks that should pay predictable dividends that grow…
5 Aug 2022
Share tips of the week – 5 August
Share tips

Share tips of the week – 5 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
5 Aug 2022
Invest in defence stocks as war goes hi-tech
Share tips

Invest in defence stocks as war goes hi-tech

The operational efficiency of defence equipment and cybersecurity is developing rapidly owing to the war in Ukraine, says Jonathan Compton. Here’s wha…
4 Aug 2022

Most Popular

Are UK house prices finally heading for a crash?
House prices

Are UK house prices finally heading for a crash?

The latest house price figures show a fall of 0.1% in July. With interest rates rising, inflation hitting double figures and a recession on the cards,…
5 Aug 2022
Brace yourself for the return of rationing
Economy

Brace yourself for the return of rationing

Russia is turning off the cheap energy. That is already leading to belt-tightening, says Matthew Lynn. Who will suffer most, and which sectors will th…
5 Aug 2022
Zhao Weiguo: China’s No. 1 chip tycoon vanishes
People

Zhao Weiguo: China’s No. 1 chip tycoon vanishes

Zhao Weiguo rode a decades-long boom in China pursuing Beijing’s core industrial policy of semiconductor self-sufficiency. Then he fell foul of Xi Jin…
5 Aug 2022